Abstract
Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin’s anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual low-dose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12 months of treatment (-0.12 mm [SD = 1.55 mm] and +0.30 mm [SD= 2.54 mm], respectively; 2-sided P = .33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.
Highlights
Helical low-dose computed tomography screening can detect early-stage lung cancers, resulting in a 20% decrease in lung cancer mortality (3,4)
Within CT screening programs, noncalcified nodules have been shown to be associated with increased cancer risk
Focusing on persistent SSNs detected with low-dose computed tomography (ld-CT), a phase IIb randomized study was performed to assess aspirin’s effect on nodule size and other surrogate biomarkers
Summary
Helical low-dose computed tomography (ld-CT) screening can detect early-stage lung cancers, resulting in a 20% decrease in lung cancer mortality (3,4). Focusing on persistent SSNs detected with ld-CT, a phase IIb randomized study was performed to assess aspirin’s effect on nodule size and other surrogate biomarkers.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
